The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...

NHS Sussex is encouraging eligible residents to come forward for their free respiratory syncytial virus (RSV) vaccination.